i

Class IIa indication for cardiac resynchronization therapy for reducing the risk of HF worsening:

- CHF + NYHA Class III- IV persisting despite optimal pharmacotherapy + permanent AF + QRS duration of > 0,12 s + LVEF < 35% + patients in whom expected survival time with good functional status is > 1 year + undergoing AV nodal ablation.

Class IIb indications for cardiac resynchronization therapy for reducing the risk of HF worsening:

- CHF + NYHA Class III- IV persisting despite optimal pharmacotherapy + permanent AF + intrinsically slow ventricular rate requiring pacing + QRS duration of > 0,12 s  + LVEF < 35% + patients in whom expected survival time with good functional status is > 1 year,
- CHF + NYHA Class III- IV persisting despite optimal pharmacotherapy + permanent AF + ventricular rate at rest < 60 b.p.m. + ventricular rate on exercise < 90 b.p.m. + QRS duration of > 0,12 s + LVEF < 35% + patients in whom expected survival time with good functional status is > 1 year.